Life Technologies Corporation

Life Technologies Corporation, operating as Thermo Fisher Scientific, manufactures and supplies laboratory instrumentation, reagents, consumables, and comprehensive maintenance services to federal agencies as a prime contractor across scientific instrumentation, genetic analysis, molecular biology, and diagnostic sectors. The company competes full-and-open across its federal footprint with no SBA set-aside posture; it is a for-profit organization and subsidiary of Thermo Fisher Scientific Inc. headquartered in Waltham, Massachusetts, with Life Technologies maintaining operations in Carlsbad, California.

Life Technologies' federal customer base spans 169 agencies concentrated heavily in health and research missions. The top five customers by award count—Department of Health and Human Services National Institutes of Health Office of the Director (1,434 awards, $10.8 million), NIAID (518 awards, $12.4 million), National Institute of Environmental Health Sciences (479 awards, $18.3 million), Centers for Disease Control and Prevention Office of Acquisition Services (408 awards, $10.1 million), and CDC Pittsburgh (390 awards, $70.1 million)—account for 21% of awards. However, the top five by combined potential value diverge: Department of the Army Medical Command ($83 million across 168 awards), CDC Pittsburgh ($70.1 million across 390 awards), NIH Office of Logistics and Acquisition Operations ($54.7 million across 381 awards), Department of the Army Criminal Investigation Command ($53.1 million across 255 awards), and USDA Agricultural Research Service ($28.2 million across 281 awards) represent 23% of combined potential value. This pattern reflects Life Technologies' strength in supplying high-value equipment, reagents, and maintenance services to defense medical operations and large federal research infrastructure.

Life Technologies' representative prime work spans product sales and preventative maintenance agreements. Named examples include a $9.8 million delivery order from an unidentified Headquarters Division civilian agency in March 2026 for consumables and reagents; a $842 thousand sole-source purchase order from the FBI for three 3500XL Genetic Analyzers in June 2025; $750 thousand in PCR kits to USDA Veterinary Services in May 2025; a $483 thousand delivery order to USDA Veterinary Services for PCR reagents for animal disease diagnostics in June 2025; a $358 thousand Defense Health Agency contract for HIV screening and supplemental testing equipment maintenance through 2030; and recurring maintenance agreements valued at $100 thousand to $300 thousand annually with VA, Navy Bureau of Medicine and Surgery, and CDC facilities for QuantStudio, Attune, Kingfisher, and ABI genetic analyzer systems. SCI-reported federal service contract invoicing reached $1.4 million in FY2022, $1.8 million in FY2023, and $0 in FY2024; the vendor deployed approximately 0.6 FTEs in FY2022 and 1.0 FTE in FY2023 on SCI-reportable contracts. Median government-paid hourly rates on service contracts run around $1,070/hr, with senior labor pricing extending to $2,000/hr. Life Technologies operates as a prime on its service contracts with minimal sub-engagement—SCI data shows 0% average sub-hours share, indicating the company builds and delivers its own service teams.

Life Technologies holds two named parent vehicles: a single-award Blanket Purchase Agreement with Bureau of Alcohol, Tobacco, Firearms and Explosives valued at $2.4 million through May 2031 for forensic DNA analysis reagents and supplies at the Wichita laboratory, and a single-award IDIQ with Veterans Integrated Service Network 16 valued at $83.2 thousand through September 2030 for genetic analyzer maintenance. Across the broader award portfolio, the top parent vehicles reflect Life Technologies' deep positioning in NIH and USDA procurement: BPA HHSN263201200063B carries 2,008 task orders ($23.8 million combined potential value), BPA HHSN263200200056213B carries 1,388 task orders ($4 million), USDA Indefinite Delivery Contract 1232SA21D0001 carries 252 task orders ($22.2 million), and Defense Health Agency BPA HHSD2002017M94460B carries 152 task orders ($10.7 million). Recent award velocity shows 359 prime awards in 2022, declining through 301 in 2023, 325 in 2024, 196 in 2025, and 47 in 2026 (through August). Awards completing in the next twenty-four months total 155 with combined potential value of $62 million, presenting significant recompete exposure.

Life Technologies' capability portfolio centers on biotechnology infrastructure: QuantStudio, Viia7, and QuantStudio Flex real-time PCR systems; 3500XL, 3730C, and Genetitan genetic analyzers; ABI genetic sequencers; Attune flow cytometry equipment; Kingfisher nucleic acid extraction and purification systems; Ion Chef and Ion Torrent sequencing platforms; EVOS imaging systems; Luminex XMAP INTELLIFLEX multiplexing instruments; and Varioskan spectrophotometry systems. The company supplies associated consumables including PCR kits, BigDye Terminator sequencing reagents, MAGMAX and Ion AmpliSeq nucleic acid purification kits, cell culture media, antibodies, and laboratory buffers. Service offerings span preventative maintenance plans (typically annual or multi-year), operational qualification and installation qualification services, parts replacement, priority technical support with guaranteed response times (often 2 business days), software updates, and calibration and alignment services. Representative consumables work includes a $750 thousand PCR kit delivery to USDA Veterinary Services, $296 thousand MAGMAX nucleic acid purification kit deliveries to USDA Veterinary Services across multiple fiscal years, and $483 thousand in PCR reagents for veterinary diagnostics. Maintenance represents the largest share of service revenue: contracts routinely span 3 to 5 years with annual service values of $20 thousand to $100 thousand per instrument, often including multiple government-owned systems at single facilities.

Life Technologies operates primarily as a prime contractor; the award portfolio shows 15,443 prime awards (100% of total) against 6 sub-awards (0%), indicating the company does not rely on subcontracting to deliver federal work. The two named sub-awards visible in the source are a June 2025 sub-engagement with Battelle Memorial Institute on advanced threats research, development, test, and evaluation for joint CBRN defense, and an August 2025 sub-award under Attorney General of Ohio for lab supplies and service agreements. This prime-heavy posture suggests Life Technologies' business model centers on direct federal sales of its proprietary instrumentation and reagents rather than integration into larger prime contractors' solutions.

The corporate structure shows Life Technologies as a subsidiary of Thermo Fisher Scientific Inc.; the parent holds nine named subsidiaries including Invitrogen Federal Systems, Geneart AG, Biotrove, Ion Torrent Systems Incorporated, Applied Biosystems LLC, Molecular Probes Inc., Westover Scientific Inc., and Compendia Bioscience. This structure allows cross-selling of complementary products under multiple brand names and consolidates federal contract administration under the Thermo Fisher parent. Life Technologies' NAICS profile concentrates on Biological Product Manufacturing (2,954 awards), Analytical Laboratory Instrument Manufacturing (2,566 awards), and In-Vitro Diagnostic Substance Manufacturing (1,930 awards), with maintenance work classified under Electronic and Precision Equipment Repair (1,358 awards). PSC coding aligns with Laboratory Equipment and Supplies (5,728 awards), Drugs and Biologicals (3,242 awards), and Maintenance/Repair of Instruments and Laboratory Equipment (1,670 awards). The concentration reflects the company's role as a dominant federal supplier of life-sciences research and diagnostic infrastructure, with particular strength in NIH-funded research, CDC diagnostic testing, USDA veterinary diagnostics, and DoD military medical readiness systems.